All In Biotech

Drug Trial Radar · NCT03927495

KN046 in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

Phase II Study of KN046 in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma to Evaluate Safety, Efficacy and Tolerance

Last checked: Nov 19, 2026Latest source record: May 29, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

100

Planned (sponsor's estimate)

Start

May 22, 2019

Primary completion

Jun 30, 2021

Study completion Dec 31, 2021

Sponsor

Lead sponsor
Shanghai Chest HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
First Affiliated Hospital of Suzhou Medical College
First posted
Apr 25, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, phase II study of KN046 combined with chemotherapy and palliative radiotherapy in patients with recurrent or metastatic esophageal squamous cell carcinoma to evaluate the safety, efficacy and tolerance.

Conditions

  • Esophageal Squamous Cell Carcinoma

Interventions

  • KN046Drug

    Cisplatin+paclitaxel will be administered once every three weeks for four cycles. During the period of radiotherapy, KN046 will be administered once every two weeks until progressive disease, unacceptable toxicity or up to 2 years.

  • palliative radiotherapyRadiation

    3D conformal radiation therapy will be administered for esophageal lesion or nearby lymph node. Stereotactic body radiation will be administered for metastatic lesion.

  • KN046Drug

    Cisplatin+paclitaxel will be administered once every three weeks for four cycles. After completion of radiotherapy, KN046 will be administered once every two weeks until progressive disease, unacceptable toxicity or up to 2 years.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. dose-limiting toxicity KN046Time frame: 28 days after first dose
  2. 6-month progression free survival rate assessed by investigator based on RECIST 1.1Time frame: 6 months after first dose
  3. Objective response rate assessed by investigator based on RECIST 1.1Time frame: 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Suzhou University

    Suzhou, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.